EE04097B1 - Epiteliaal-adhesiivsed laktobatsillid - Google Patents

Epiteliaal-adhesiivsed laktobatsillid

Info

Publication number
EE04097B1
EE04097B1 EE9700329A EE9700329A EE04097B1 EE 04097 B1 EE04097 B1 EE 04097B1 EE 9700329 A EE9700329 A EE 9700329A EE 9700329 A EE9700329 A EE 9700329A EE 04097 B1 EE04097 B1 EE 04097B1
Authority
EE
Estonia
Prior art keywords
pct
mannose
date sep
sec
strain
Prior art date
Application number
EE9700329A
Other languages
English (en)
Estonian (et)
Other versions
EE9700329A (et
Inventor
Adlerberth Ingegerd
Ahrn� Siv
Jeppsson Bengt
Johansson Marie-Louise
Molin G�ran
Wold Agnes
Original Assignee
Probi Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Probi Ab filed Critical Probi Ab
Publication of EE9700329A publication Critical patent/EE9700329A/xx
Publication of EE04097B1 publication Critical patent/EE04097B1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A90/00—Technologies having an indirect contribution to adaptation to climate change
    • Y02A90/10—Information and communication technologies [ICT] supporting adaptation to climate change, e.g. for weather forecasting or climate simulation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Immobilizing And Processing Of Enzymes And Microorganisms (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
  • Adhesives Or Adhesive Processes (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
EE9700329A 1995-03-23 1996-03-25 Epiteliaal-adhesiivsed laktobatsillid EE04097B1 (et)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE9501056A SE9501056D0 (sv) 1995-03-23 1995-03-23 Epithelial adherent lactobacilli
PCT/SE1996/000372 WO1996029083A1 (en) 1995-03-23 1996-03-25 Epithelial adhesive lactobacilli

Publications (2)

Publication Number Publication Date
EE9700329A EE9700329A (et) 1998-06-15
EE04097B1 true EE04097B1 (et) 2003-08-15

Family

ID=20397666

Family Applications (1)

Application Number Title Priority Date Filing Date
EE9700329A EE04097B1 (et) 1995-03-23 1996-03-25 Epiteliaal-adhesiivsed laktobatsillid

Country Status (16)

Country Link
US (1) US6159465A (de)
EP (1) EP0817640B1 (de)
JP (1) JP4072646B2 (de)
KR (1) KR100446482B1 (de)
CN (1) CN1138551C (de)
AT (1) ATE240738T1 (de)
AU (1) AU702705B2 (de)
BR (1) BR9607538A (de)
CA (1) CA2216150C (de)
DE (1) DE69628288T2 (de)
EE (1) EE04097B1 (de)
ES (1) ES2200057T3 (de)
NO (1) NO974371L (de)
PL (1) PL184037B1 (de)
SE (1) SE9501056D0 (de)
WO (1) WO1996029083A1 (de)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100376954B1 (ko) * 1995-07-31 2003-07-18 프로비 에이비 장에서집락화하는유산간균
ES2168785T5 (es) * 1997-07-05 2009-04-16 Societe Des Produits Nestle S.A. Absorcion de minerales por las celulas intestinales.
FI974643L (fi) * 1997-12-30 1999-07-01 Atria Oyj Biologinen menetelmä salmonellan eliminoimiseksi prosesseista ja rakenteista
EP1117414A1 (de) * 1998-10-01 2001-07-25 Probi Ab Reduktion von faktoren des oxidativen stresses
WO2001010448A1 (en) * 1999-08-09 2001-02-15 University Of Maryland, Baltimore Pro-gut maturation and anti-inflammatory effects of lactobacillus and lactobacillus secreted proteins, carbohydrates and lipids
WO2001030365A1 (en) * 1999-10-26 2001-05-03 Societe Des Produits Nestle S.A. Lactic acid bacteria for the treatment and/or prophylaxis of giardiasis
GB2369777B (en) * 2000-10-05 2004-10-27 St Ivel Ltd Food products with antimicrobial lactic acid bacteria
SE0004124D0 (sv) * 2000-11-10 2000-11-10 Probi Ab New use
FR2831555A1 (fr) * 2001-10-29 2003-05-02 Ceva Sante Animale Procede de selection de souches de bacteries lactiques a gram positif non pathogenes capables de lutter contre des infections par des bacteries pathogenes
FR2826020B1 (fr) * 2001-06-14 2005-02-11 Ceva Sante Animale Procede de selection de souches de bacteries lactiques a gram positif non pathogenes capables de lutter contre des infections par des bacteries pathogenes
CZ20033384A3 (cs) * 2001-06-14 2004-04-14 Ceva Sante Animale Způsob selekce kmenů nepatogenních grampozitivních mléčných bakterií
SE527555C2 (sv) * 2003-04-04 2006-04-11 Probi Ab Anti-inflammatorisk komposition innehållande tannasproducerande Lactobacillusstammar
WO2005086870A2 (en) * 2004-03-10 2005-09-22 The Board Of Trustees Of The University Of Illinois Novel lactobacillus strains and method of use
DE602005020915D1 (de) * 2004-03-23 2010-06-10 Friesland Brands Bv Mannose-spezifische adhesinen und deren vervendung
SE528382C2 (sv) * 2004-10-05 2006-10-31 Probi Ab Probiotiska lactobacillusstammar för förbättrad vaginal hälsa
JP2006180836A (ja) * 2004-12-28 2006-07-13 Marudai Food Co Ltd 食中毒菌感染を抑制する乳酸菌、ならびにそれを含む発酵物、食品および医薬組成物
JP2006257077A (ja) * 2005-02-18 2006-09-28 Marudai Food Co Ltd 免疫調節剤および免疫調節食品
CN1888051B (zh) * 2005-06-28 2010-05-05 北京天佑达生物工程科技有限公司 一株植物乳杆菌及其应用
SE529199C2 (sv) * 2005-07-05 2007-05-29 Probi Ab Förstärkt absorption
CA2622951A1 (en) 2005-09-28 2007-04-05 Nordisk Rebalance A/S Treatment of ibd and ibs using both probiotic bacteria and fermented cereal as treatment effectors
AU2006325531B2 (en) 2005-12-13 2012-04-19 Exthera Medical Corporation Method for extracorporeal removal of a pathogenic microbe, an inflammatory cell or an inflammatory protein from blood
PL210465B1 (pl) 2007-06-04 2012-01-31 Inst Biotechnologii Surowic I Szczepionek Biomed Społka Akcyjna Zastosowanie kompozycji szczepów z rodzaju Lactobacillus
FR2928935B1 (fr) 2008-03-19 2011-05-20 Gervais Danone Sa Souche de lactobacillus rhamnosus.
EP2459203B1 (de) 2009-07-30 2018-10-31 DuPont Nutrition Biosciences ApS Milchsäurebakterien und bifidobakterien zur behandlung von endotoxämie
ES2861359T3 (es) 2009-12-01 2021-10-06 Exthera Medical Corp Dispositivo para eliminar citoquinas de la sangre con polisacáridos inmovilizados en superficie
AU2011209407B2 (en) 2010-01-28 2014-02-27 Ab-Biotics S.A. Probiotic composition for use in the treatment of bowel inflammation
WO2012112724A1 (en) 2011-02-15 2012-08-23 Exthera Medical, Llc Device and method for removal of blood-borne pathogens, toxins and inflammatory cytokines
BG66608B1 (bg) * 2011-05-04 2017-10-16 "Ел Би Булгарикум" ЕАД Полибактериален пробиотичен препарат
CN102618456B (zh) * 2012-02-28 2013-08-21 江南大学 一种能够缓解慢性酒精性肝损伤的鼠李糖乳杆菌及其用途
ES2647577T3 (es) 2012-06-13 2017-12-22 Exthera Medical Corporation Uso de heparina y carbohidratos para tratar el cáncer
JP2012184261A (ja) * 2012-06-21 2012-09-27 Snow Brand Milk Products Co Ltd 免疫増強剤
CN102827796B (zh) * 2012-09-03 2013-10-30 江南大学 一种具有排镉功能的植物乳杆菌及其用途
US9452205B2 (en) 2012-09-24 2016-09-27 Montana State University Recombinant Lactococcus lactis expressing Escherichia coli colonization factor antigen I (CFA/I) fimbriae and their methods of use
JP6648009B2 (ja) * 2013-06-24 2020-02-14 エクステラ・メディカル・コーポレーション マンノース被覆基材を含有する血液濾過システム
AU2014346668C1 (en) 2013-11-08 2018-04-26 Exthera Medical Corporation Methods for diagnosing infectious diseases using adsorption media
DE15782250T1 (de) 2014-04-24 2017-08-10 Exthera Medical Corporation Verfahren zur Entfernung von Bakterien aus Blut unter Verwendung einer hohen Durchflussrate
CN106714669B (zh) 2014-09-22 2021-05-14 艾克塞拉医疗公司 可穿戴的血液灌流装置
RU2709464C2 (ru) 2015-09-29 2019-12-18 Кимберли-Кларк Ворлдвайд, Инк. Синергическая композиция для сохранения здорового баланса микрофлоры
EP3422943A4 (de) 2016-03-02 2019-10-16 ExThera Medical Corporation Verfahren zur behandlung von arzneimittelintoxikation
US11911551B2 (en) 2016-03-02 2024-02-27 Exthera Medical Corporation Method for treating drug intoxication
US12029748B2 (en) 2017-02-28 2024-07-09 Kimberly-Clark Worldwide, Inc. Synergistic composition for maintenance of healthy balance of microflora
WO2019103198A1 (ko) 2017-11-24 2019-05-31 주식회사 고바이오랩 락토바실러스 퍼멘텀 kbl 375 균주 및 그 용도
CN112534043B (zh) 2018-05-09 2024-04-26 Ko生物技术有限公司 副干酪乳杆菌菌株及其用途
JP7088573B2 (ja) 2018-05-23 2022-06-21 コバイオラブズ・インコーポレイテッド ラクトバチルス・ガッセリーｋｂｌ６９７株及びその使用
EP3969014A4 (de) 2019-05-16 2023-01-25 ExThera Medical Corporation Verfahren zur modulation der endothelialen glycocalyxstruktur
CN114007434A (zh) 2019-06-05 2022-02-01 森永乳业株式会社 营养组合物
CN111575223B (zh) * 2020-05-20 2022-04-15 江南大学 一种降低鼠李糖乳杆菌表面物质分泌量的方法
CN119242500A (zh) * 2024-09-30 2025-01-03 尚品健康科技(青岛)有限公司 一株母乳来源植物乳植杆菌改善过敏性疾病和调节肠道菌群的应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0203586A3 (de) * 1985-05-29 1988-03-09 Pioneer Hi-Bred International Zubereitung für die Behandlung von Magen-/Darmstörungen bei Tieren
SE469875C (sv) * 1991-07-25 1997-04-14 Probi Ab Stam av tarmkoloniserande Lactobacillus samt komposition för profylax eller behandling av infektioner i magtarmkanalen
GB9124249D0 (en) * 1991-11-14 1992-01-08 Goldstein Fredric Ribbon curling and shredding device
GB2261372A (en) * 1991-11-15 1993-05-19 Gregor Reid Lactobacillus and skim milk compositions for prevention of urogenital infection

Also Published As

Publication number Publication date
CA2216150C (en) 2008-01-22
DE69628288D1 (de) 2003-06-26
CA2216150A1 (en) 1996-09-26
CN1185111A (zh) 1998-06-17
KR19980703102A (ko) 1998-10-15
ES2200057T3 (es) 2004-03-01
AU702705B2 (en) 1999-03-04
WO1996029083A1 (en) 1996-09-26
HK1017989A1 (en) 1999-12-10
CN1138551C (zh) 2004-02-18
PL322550A1 (en) 1998-02-02
US6159465A (en) 2000-12-12
DE69628288T2 (de) 2004-04-08
NO974371L (no) 1997-11-20
SE9501056D0 (sv) 1995-03-23
EE9700329A (et) 1998-06-15
BR9607538A (pt) 1998-01-06
NO974371D0 (no) 1997-09-22
PL184037B1 (pl) 2002-08-30
JP4072646B2 (ja) 2008-04-09
JPH11502703A (ja) 1999-03-09
EP0817640A1 (de) 1998-01-14
AU5166596A (en) 1996-10-08
ATE240738T1 (de) 2003-06-15
EP0817640B1 (de) 2003-05-21
KR100446482B1 (ko) 2006-01-27

Similar Documents

Publication Publication Date Title
EE9700329A (et) Epiteliaal-adhesiivsed laktobatsillid
Ogawa et al. Inhibition of Streptococcus mutans biofilm formation by Streptococcus salivarius FruA
Jensen et al. In vitro testing of commercial and potential probiotic lactic acid bacteria
TR200101699T2 (tr) Urogenital enfeksiyonların önlenmesi ve tedavisi için ağızdan lactobakilus uygulaması
AU6040001A (en) Use of hydrogenotrophic acetogenic strains for preventing or treating digestive disorders
HUT75555A (en) Lactobacillus strains of human origin, their compositions and uses thereof
EA200101262A1 (ru) Диетическая или фармацевтическая композиция для применения в целях профилактики или лечения гипероксалурии
Neilands et al. Parvimonas micra stimulates expression of gingipains from Porphyromonas gingivalis in multi-species communities
WO2002083879A3 (en) Immunotherapy based on dendritic cells
Melgar-Lalanne et al. In vitro evaluation of the probiotic potential of halotolerant lactobacilli isolated from a ripened tropical Mexican cheese
NZ335086A (en) Bacillus thuringiensis pesticidal toxins and nucleotide sequences which encode these toxins
EE9700269A (et) Farmatseutiline kompositsioon, mis sisaldab Lactobacillus plantarum'it ja arginiini
MY140870A (en) Nutrition supplement containing lactobacillus acidophilus, yeast and soy protein
Henriksson et al. Adhesion of Lactobacillus fermentum 104-S to porcine stomach mucus
DK0858501T3 (da) Mælkesyrebakteriepræparater samt deres anvendelse til fremstilling af kolesterolsænkende produkter
Titball et al. Partial purification and properties of a haemolytic activity (T-lysin) from Aeromonas salmonicida
Ouwehand et al. Specificity of spent culture fluids of Lactobacillus spp. to inhibit adhesion of enteropathogenic fimbriated Escherichia coli cells
AU5069500A (en) Use of lactic acid bacteria in the preparation of fermented milks for the treatment of depressed immunity levels
Hryniewicz et al. The first national external quality assessment scheme in clinical bacteriology in Poland(POLMicro I)
LeVatte Repression of the Pseudomonas aeruginosa ferripyochelin-binding protein expression by subinhibitory concentrations of antibiotics
Fiuzat Study of Lactobacillus reuteri in vitro, in situ and in the gastrointestinal tract of CD-1 mice.
Sriyosachati Iron Mobilization from Transferrin by Pseudomonas Aeruginosa
HAYES Purification and Mode of Action of a Bacteriocin Produced by Bacteroides Fragilis
MD781B1 (en) Selective medium for separation of Streptococcus bacteries
MD1305B2 (en) Nutrient medium for selective separation of the Enterobacteriaceae family representatives

Legal Events

Date Code Title Description
KB4A Valid patent at the end of a year

Effective date: 20031231

KB4A Valid patent at the end of a year

Effective date: 20041231

KB4A Valid patent at the end of a year

Effective date: 20051231

KB4A Valid patent at the end of a year

Effective date: 20061231

KB4A Valid patent at the end of a year

Effective date: 20071231

KB4A Valid patent at the end of a year

Effective date: 20081231

KB4A Valid patent at the end of a year

Effective date: 20091231

KB4A Valid patent at the end of a year

Effective date: 20101231